

Steven G Deeks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/656291/publications.pdf>

Version: 2024-02-01

592
papers

61,929
citations

704

125
h-index

1551

223
g-index

643
all docs

643
docs citations

643
times ranked

38946
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2022, 74, 95-104.	2.9	31
2	Short Communication: A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 127-130.	0.5	3
3	Cellular Activation, Differentiation, and Proliferation Influence the Dynamics of Genetically Intact Proviruses Over Time. <i>Journal of Infectious Diseases</i> , 2022, 225, 1168-1178.	1.9	9
4	Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies. <i>Clinical Infectious Diseases</i> , 2022, 74, 865-870.	2.9	30
5	Cell-Associated Human Immunodeficiency Virus (HIV) Ribonucleic Acid Has a Circadian Cycle in Males With HIV on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2022, 225, 1721-1730.	1.9	7
6	Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 221-226.	1.7	53
7	Deep Phenotypic Analysis of Blood and Lymphoid T and NK Cells From HIV+ Controllers and ART-Suppressed Individuals. <i>Frontiers in Immunology</i> , 2022, 13, 803417.	2.2	12
8	Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. <i>Science Translational Medicine</i> , 2022, 14, eabl3836.	5.8	50
9	IFN- γ blockade during ART-treated SIV infection lowers tissue vDNA, rescues immune function, and improves overall health. <i>JCI Insight</i> , 2022, 7, .	2.3	6
10	The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	52
11	Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e916-e919.	2.9	42
12	Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses. <i>Nature Immunology</i> , 2022, 23, 360-370.	7.0	34
13	Plasma-Derived HIV-1 Virions Contain Considerable Levels of Defective Genomes. <i>Journal of Virology</i> , 2022, 96, jvi0201121.	1.5	18
14	Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 510-517.	0.5	4
15	Gut-derived bacterial toxins impair memory CD4+ T cell mitochondrial function in HIV-1 infection. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	13
16	SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19. <i>Annals of Neurology</i> , 2022, 91, 772-781.	2.8	63
17	Findings From Mayo Clinic's Post-COVID Clinic: PASC Phenotypes Vary by Sex and Degree of IL-6 Elevation. <i>Mayo Clinic Proceedings</i> , 2022, 97, 430-432.	1.4	8
18	First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody. <i>Nature Communications</i> , 2022, 13, 1219.	5.8	20

#	ARTICLE	IF	CITATIONS
19	The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infectionâ€”study protocol for a two-stage randomised phase II trial. <i>Trials</i> , 2022, 23, 263.	0.7	6
20	Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. <i>JCI Insight</i> , 2022, 7, .	2.3	24
21	Early clues regarding the pathogenesis of long-COVID. <i>Trends in Immunology</i> , 2022, 43, 268-270.	2.9	79
22	Ethical and practical considerations for cell and gene therapy toward an HIV cure: findings from a qualitative in-depth interview study in the United States. <i>BMC Medical Ethics</i> , 2022, 23, 39.	1.0	2
23	Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab640.	0.4	56
24	Characterizing the COVID-19 Illness Experience to Inform the Study of Post-acute Sequelae and Recovery. <i>International Journal of Behavioral Medicine</i> , 2022, 29, 610-623.	0.8	9
25	Variation in blood microbial lipopolysaccharide (LPS) contributes to immune reconstitution in response to suppressive antiretroviral therapy in HIV. <i>EBioMedicine</i> , 2022, 80, 104037.	2.7	13
26	CE-541-04 CARDIAC ARRHYTHMIAS IN POST-ACUTE SEQUELAE OF SARS-COV-2 INFECTION ASSESSED BY AMBULATORY RHYTHM MONITORING. <i>Heart Rhythm</i> , 2022, 19, S54-S55.	0.3	0
27	Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events. <i>EBioMedicine</i> , 2022, 80, 104072.	2.7	9
28	Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF- κ B signaling. <i>JCI Insight</i> , 2022, 7, .	2.3	23
29	Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	3.1	41
30	Magnitude and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Household Transmission: A Longitudinal Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, S193-S204.	2.9	9
31	Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size. <i>Journal of Infectious Diseases</i> , 2021, 224, 1209-1218.	1.9	18
32	Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective study. <i>American Journal of Transplantation</i> , 2021, 21, 1765-1779.	2.6	14
33	NIH Workshop on HIV-Associated Comorbidities, Coinfections, and Complications: Summary and Recommendation for Future Research. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 11-18.	0.9	11
34	Abnormal Levels of Some Biomarkers of Immune Activation Despite Very Early Treatment of Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2021, 223, 1621-1630.	1.9	20
35	Operationalizing Human Immunodeficiency Virus Cure-related Trials with Analytic Treatment Interruptions During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: A Collaborative Approach. <i>Clinical Infectious Diseases</i> , 2021, 72, 1843-1849.	2.9	15
36	The case for an HIV cure and how to get there. <i>Lancet HIV</i> , 2021, 8, e51-e58.	2.1	46

#	ARTICLE	IF	CITATIONS
37	Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 1839-1848.	1.9	176
38	Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations. <i>Cells</i> , 2021, 10, 386.	1.8	125
39	Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. <i>Journal of NeuroVirology</i> , 2021, 27, 191-195.	1.0	95
40	TCF-1 regulates HIV-specific CD8+ T cell expansion capacity. <i>JCI Insight</i> , 2021, 6, .	2.3	43
41	Antigen-driven clonal selection shapes the persistence of HIV-1-infected CD4+ T cells in vivo. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	103
42	Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. <i>EBioMedicine</i> , 2021, 65, 103241.	2.7	24
43	Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response. <i>Journal of Infectious Diseases</i> , 2021, 224, 1593-1598.	1.9	14
44	Evaluating a New Class of AKT/mTOR Activators for HIV Latency-Reversing Activity <i>Ex Vivo</i> and <i>In Vivo</i> . <i>Journal of Virology</i> , 2021, 95, .	1.5	13
45	Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e1973-e1981.	2.9	34
46	CpG Methylation Profiles of HIV-1 Proviral DNA in Individuals on ART. <i>Viruses</i> , 2021, 13, 799.	1.5	6
47	Characterization of HIV-induced remodeling reveals differences in infection susceptibility of memory CD4+ T cell subsets in vivo. <i>Cell Reports</i> , 2021, 35, 109038.	2.9	15
48	A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoir. <i>Cell Reports Medicine</i> , 2021, 2, 100243.	3.3	44
49	Brief Report: Lower Socioeconomic Status Associates With Greater Systemic and Arterial Inflammation in HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 706-710.	0.9	1
50	The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	35
51	Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 489-501.	0.5	4
52	Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab393.	0.4	3
53	SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. <i>Science Advances</i> , 2021, 7, .	4.7	117
54	SARS-CoV-2 Vaccination in the Context of Ongoing HIV Cure-Related Research Studies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, e232-e233.	0.9	2

#	ARTICLE	IF	CITATIONS
55	HIV Antibody Profiles in HIV Controllers and Persons With Treatment-Induced Viral Suppression. <i>Frontiers in Immunology</i> , 2021, 12, 740395.	2.2	6
56	Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. <i>Cell Reports</i> , 2021, 36, 109518.	2.9	142
57	HIV-1 Genomes Are Enriched in Memory CD4 ⁺ T-Cells with Short Half-Lives. <i>MBio</i> , 2021, 12, e0244721.	1.8	11
58	Functional impairment of HIV-specific CD8 ⁺ T cells precedes aborted spontaneous control of viremia. <i>Immunity</i> , 2021, 54, 2372-2384.e7.	6.6	20
59	Multi-stakeholder consensus on a target product profile for an HIV cure. <i>Lancet HIV</i> , 2021, 8, e42-e50.	2.1	38
60	Genome-wide DNA methylation profiling of peripheral blood reveals an epigenetic signature associated with severe COVID-19. <i>Journal of Leukocyte Biology</i> , 2021, 110, 21-26.	1.5	82
61	Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART. <i>PLoS Pathogens</i> , 2021, 17, e1009214.	2.1	25
62	Universal Polymerase Chain Reaction and Antibody Testing Demonstrate Little to No Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in a Rural Community. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa531.	0.4	9
63	Losartan to reduce inflammation and fibrosis endpoints in HIV disease. <i>Aids</i> , 2021, 35, 575-583.	1.0	11
64	Considerations for designing and implementing combination HIV cure trials: findings from a qualitative in-depth interview study in the United States. <i>AIDS Research and Therapy</i> , 2021, 18, 75.	0.7	6
65	Effect of HIV Infection on Angiotensin 1 and 2 Levels and Measures of Microvascular and Macrovascular Endothelial Dysfunction. <i>Journal of the American Heart Association</i> , 2021, 10, e021397.	1.6	5
66	Identification and Characterization of Antigen-Specific CD8 ⁺ T Cells Using Surface-Trapped TNF- α and Single-Cell Sequencing. <i>Journal of Immunology</i> , 2021, , j2100535.	0.4	2
67	SARS-CoV-2 booster vaccination for participants in HIV cure-related clinical trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, e30.	0.9	1
68	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. <i>Nature Medicine</i> , 2021, 27, 2085-2098.	15.2	146
69	Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers. <i>Science Translational Medicine</i> , 2021, 13, eabl4097.	5.8	52
70	Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2020, 70, 1176-1185.	2.9	27
71	Circulating CD30 ⁺ CD4 ⁺ T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption. <i>Journal of Infectious Diseases</i> , 2020, 221, 1146-1155.	1.9	11
72	High levels of genetically intact HIV in HLA-DR ⁺ memory T cells indicates their value for reservoir studies. <i>Aids</i> , 2020, 34, 659-668.	1.0	32

#	ARTICLE	IF	CITATIONS
73	Plasma tissue factor and immune activation are associated with carotid intima-media thickness progression in treated HIV infection. <i>Aids</i> , 2020, 34, 519-528.	1.0	4
74	Human Immunodeficiency Virus (HIV)-Infected CCR6+ Rectal CD4+ T Cells and HIV Persistence On Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 744-755.	1.9	39
75	Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1. <i>Journal of Virus Eradication</i> , 2020, 6, 19-26.	0.3	6
76	A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption. <i>Journal of Virus Eradication</i> , 2020, 6, 34-37.	0.3	26
77	Mining for humoral correlates of HIV control and latent reservoir size. <i>PLoS Pathogens</i> , 2020, 16, e1008868.	2.1	19
78	Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18692-18700.	3.3	67
79	A High Percentage of People With Human Immunodeficiency Virus (HIV) on Antiretroviral Therapy Experience Detectable Low-Level Plasma HIV-1 RNA Following Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 2020, 73, e2845-e2846.	2.9	6
80	HLA tapasin independence: broader peptide repertoire and HIV control. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28232-28238.	3.3	51
81	Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents. <i>Aids</i> , 2020, 34, 2013-2024.	1.0	14
82	Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103 ⁺ and Gut CD4 ⁺ T Cells. <i>Journal of Virology</i> , 2020, 95, .	1.5	4
83	Distinct viral reservoirs in individuals with spontaneous control of HIV-1. <i>Nature</i> , 2020, 585, 261-267.	13.7	245
84	The Current State of HIV and Aging: Findings Presented at the 10th International Workshop on HIV and Aging. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 973-981.	0.5	11
85	Replicate Aptima Assay for Quantifying Residual Plasma Viremia in Individuals on Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	10
86	Association of Viral Persistence and Atherosclerosis in Adults With Treated HIV Infection. <i>JAMA Network Open</i> , 2020, 3, e2018099.	2.8	20
87	Delayed Expression of PD-1 and TIGIT on HIV-Specific CD8 T Cells in Untreated HLA-B*57:01 Individuals Followed from Early Infection. <i>Journal of Virology</i> , 2020, 94, .	1.5	5
88	CXCR4-Using HIV Strains Predominate in Naive and Central Memory CD4 ⁺ T Cells in People Living with HIV on Antiretroviral Therapy: Implications for How Latency Is Established and Maintained. <i>Journal of Virology</i> , 2020, 94, .	1.5	18
89	“Rinse and Replace™: Boosting T Cell Turnover To Reduce HIV-1 Reservoirs. <i>Trends in Immunology</i> , 2020, 41, 466-480.	2.9	26
90	Single-cell transcriptional landscapes reveal HIV-1-driven aberrant host gene transcription as a potential therapeutic target. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	75

#	ARTICLE	IF	CITATIONS
91	FOXO1 promotes HIV latency by suppressing ER stress in T cells. <i>Nature Microbiology</i> , 2020, 5, 1144-1157.	5.9	18
92	Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1837-1842.	1.9	3
93	Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1604-1610.	1.3	8
94	Beta cell-specific CD8+ T cells maintain stem cell memory-associated epigenetic programs during type 1 diabetes. <i>Nature Immunology</i> , 2020, 21, 578-587.	7.0	63
95	Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 530-537.	0.9	17
96	HIV-1-induced cytokines deplete homeostatic innate lymphoid cells and expand TCF7-dependent memory NK cells. <i>Nature Immunology</i> , 2020, 21, 274-286.	7.0	60
97	Different human resting memory CD4 ⁺ T cell subsets show similar low inducibility of latent HIV-1 proviruses. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	73
98	Association between statin use, atherosclerosis, and mortality in HIV-infected adults. <i>PLoS ONE</i> , 2020, 15, e0232636.	1.1	3
99	Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection. <i>PLoS Pathogens</i> , 2020, 16, e1008450.	2.1	34
100	The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies. <i>Cell Host and Microbe</i> , 2020, 27, 519-530.	5.1	173
101	Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites. <i>Journal of Virology</i> , 2020, 94, .	1.5	20
102	Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches. <i>Frontiers in Immunology</i> , 2020, 11, 519.	2.2	7
103	Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. <i>JCI Insight</i> , 2020, 5, .	2.3	140
104	Longitudinal study reveals HIV-1-infected CD4+ T cell dynamics during long-term antiretroviral therapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 3543-3559.	3.9	69
105	Filgotinib suppresses HIV-1-driven gene transcription by inhibiting HIV-1 splicing and T cell activation. <i>Journal of Clinical Investigation</i> , 2020, 130, 4969-4984.	3.9	26
106	Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop. <i>Pathogens and Immunity</i> , 2020, 5, 143.	1.4	42
107	Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir. <i>ELife</i> , 2020, 9, .	2.8	63
108	The immune response fails to control HIV early in initial virus spread. <i>Journal of Clinical Investigation</i> , 2020, 130, 2803-2805.	3.9	1

#	ARTICLE	IF	CITATIONS
109	Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1. <i>Journal of Virus Eradication</i> , 2020, 6, 19-26.	0.3	3
110	A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption. <i>Journal of Virus Eradication</i> , 2020, 6, 34-37.	0.3	17
111	Association between statin use, atherosclerosis, and mortality in HIV-infected adults. , 2020, 15, e0232636.		0
112	Association between statin use, atherosclerosis, and mortality in HIV-infected adults. , 2020, 15, e0232636.		0
113	Association between statin use, atherosclerosis, and mortality in HIV-infected adults. , 2020, 15, e0232636.		0
114	Association between statin use, atherosclerosis, and mortality in HIV-infected adults. , 2020, 15, e0232636.		0
115	Title is missing!. , 2020, 16, e1008450.		0
116	Title is missing!. , 2020, 16, e1008450.		0
117	Title is missing!. , 2020, 16, e1008450.		0
118	Title is missing!. , 2020, 16, e1008450.		0
119	Title is missing!. , 2020, 16, e1008450.		0
120	Title is missing!. , 2020, 16, e1008450.		0
121	Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV α 1 Transcription in a Phase IIb Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 692-702.	2.3	29
122	Risk to Nonparticipants in HIV Remission Studies With Treatment Interruption: A Symposium. <i>Journal of Infectious Diseases</i> , 2019, 220, S1-S4.	1.9	21
123	How Unavoidable Are Analytical Treatment Interruptions in HIV Cure-Related Studies?. <i>Journal of Infectious Diseases</i> , 2019, 220, S24-S26.	1.9	14
124	Effector memory differentiation increases detection of replication-competent HIV-1 in resting CD4+ T cells from virally suppressed individuals. <i>PLoS Pathogens</i> , 2019, 15, e1008074.	2.1	41
125	Memory CD4 + T-Cells Expressing HLA-DR Contribute to HIV Persistence During Prolonged Antiretroviral Therapy. <i>Frontiers in Microbiology</i> , 2019, 10, 2214.	1.5	38
126	Attacking Latent HIV with convertible CAR-T Cells, a Highly Adaptable Killing Platform. <i>Cell</i> , 2019, 179, 880-894.e10.	13.5	95

#	ARTICLE	IF	CITATIONS
127	Transcriptional down-regulation of ccr5 in a subset of HIV+ controllers and their family members. <i>ELife</i> , 2019, 8, .	2.8	17
128	HIV-Specific T Cell Responses Are Highly Stable on Antiretroviral Therapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 15, 9-17.	1.8	19
129	A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. <i>Nature</i> , 2019, 566, 120-125.	13.7	471
130	Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control. <i>Journal of Virology</i> , 2019, 93, .	1.5	41
131	Stimulant Use and Viral Suppression in the Era of Universal Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 89-93.	0.9	41
132	Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies. <i>Frontiers in Immunology</i> , 2019, 10, 1021.	2.2	8
133	CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome. <i>Nature Immunology</i> , 2019, 20, 824-834.	7.0	87
134	HIV –secure– A shot in the arm?. <i>EBioMedicine</i> , 2019, 42, 3-5.	2.7	11
135	Carnitine Is Associated With Atherosclerotic Risk and Myocardial Infarction in HIV–infected Adults. <i>Journal of the American Heart Association</i> , 2019, 8, e011037.	1.6	15
136	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. <i>Lancet HIV,the</i> , 2019, 6, e240-e249.	2.1	46
137	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials–report of a consensus meeting. <i>Lancet HIV,the</i> , 2019, 6, e259-e268.	2.1	139
138	Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size. <i>PLoS Computational Biology</i> , 2019, 15, e1006849.	1.5	22
139	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV–positive individuals. <i>Statistics in Medicine</i> , 2019, 38, 2428-2446.	0.8	13
140	PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals. <i>Nature Communications</i> , 2019, 10, 814.	5.8	149
141	Statistical analysis of single-copy assays when some observations are zero. <i>Journal of Virus Eradication</i> , 2019, 5, 167-173.	0.3	5
142	Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 25891-25899.	3.3	78
143	Elite control of HIV is associated with distinct functional and transcriptional signatures in lymphoid tissue CD8 ⁺ T cells. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	81
144	Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4 ⁺ T Cells. <i>Journal of Virology</i> , 2019, 93, .	1.5	72

#	ARTICLE	IF	CITATIONS
145	HIV elite control is associated with reduced TRAILshort expression. <i>Aids</i> , 2019, 33, 1757-1763.	1.0	5
146	Some Aspects of CD8+ T-Cell Exhaustion Are Associated With Altered T-Cell Mitochondrial Features and ROS Content in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 211-219.	0.9	14
147	Why and where an HIV cure is needed and how it might be achieved. <i>Nature</i> , 2019, 576, 397-405.	13.7	90
148	One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States. <i>Clinical Infectious Diseases</i> , 2019, 68, 795-802.	2.9	13
149	Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. <i>Clinical Infectious Diseases</i> , 2019, 68, 1877-1886.	2.9	42
150	Reiterative Enrichment and Authentication of CRISPRi Targets (REACT) identifies the proteasome as a key contributor to HIV-1 latency. <i>PLoS Pathogens</i> , 2019, 15, e1007498.	2.1	46
151	Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. <i>Journal of Infectious Diseases</i> , 2019, 219, 1084-1094.	1.9	73
152	HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy. <i>Journal of Clinical Investigation</i> , 2019, 129, 4629-4642.	3.9	84
153	CD32-RNA Co-localizes with HIV-RNA in CD3+ Cells Found within Gut Tissues from Viremic and ART-Suppressed Individuals. <i>Pathogens and Immunity</i> , 2019, 4, 147.	1.4	15
154	Statistical analysis of single-copy assays when some observations are zero. <i>Journal of Virus Eradication</i> , 2019, 5, 167-173.	0.3	5
155	Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?. <i>Journal of Infectious Diseases</i> , 2018, 217, 1024-1032.	1.9	29
156	Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 Infection. <i>Journal of Immunology</i> , 2018, 200, 1876-1888.	0.4	28
157	Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2018, 218, 239-248.	1.9	29
158	Elevated <i>HLA-A</i> expression impairs HIV control through inhibition of NKG2A-expressing cells. <i>Science</i> , 2018, 359, 86-90.	6.0	135
159	Detection of HIV-1-specific gastrointestinal tissue resident CD8+ T-cells in chronic infection. <i>Mucosal Immunology</i> , 2018, 11, 909-920.	2.7	38
160	Unique Circulating MicroRNA Profiles in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 644-650.	0.9	16
161	Maximising the global health impact of future HIV cure-related interventions through advance planning. <i>Journal of Virus Eradication</i> , 2018, 4, 182-185.	0.3	3
162	Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency. <i>PLoS Pathogens</i> , 2018, 14, e1007357.	2.1	76

#	ARTICLE	IF	CITATIONS
163	IL-1 β Inhibition Reduces Atherosclerotic Inflammation in HIV Infection. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2809-2811.	1.2	59
164	Ethical issues in HIV remission trials. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 422-427.	1.5	22
165	Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1. <i>Aids</i> , 2018, 32, 2119-2128.	1.0	28
166	HIV control: Is getting there the same as staying there?. <i>PLoS Pathogens</i> , 2018, 14, e1007222.	2.1	65
167	Short Communication: Dried Blood Spots Stored at Room Temperature Should Not Be Used for HIV Incidence Testing. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 1013-1016.	0.5	4
168	Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. <i>Blood Advances</i> , 2018, 2, 3479-3482.	2.5	14
169	A randomized, controlled trial of mindfulness-based stress reduction in HIV infection. <i>Brain, Behavior, and Immunity</i> , 2018, 73, 331-339.	2.0	32
170	Identification and characterization of HIV-specific resident memory CD8 ⁺ T cells in human lymphoid tissue. <i>Science Immunology</i> , 2018, 3, .	5.6	116
171	Limited immune surveillance in lymphoid tissue by cytolytic CD4 ⁺ T cells during health and HIV disease. <i>PLoS Pathogens</i> , 2018, 14, e1006973.	2.1	30
172	Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4 ⁺ T cells. <i>ELife</i> , 2018, 7, .	2.8	126
173	Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E7795-E7804.	3.3	121
174	Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. <i>Annals of Oncology</i> , 2018, 29, 2141-2142.	0.6	47
175	The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. <i>Journal of Infectious Diseases</i> , 2018, 218, 1954-1963.	1.9	130
176	Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. <i>Journal of Infectious Diseases</i> , 2018, 218, 1394-1403.	1.9	36
177	A20 upregulation during treated HIV disease is associated with intestinal epithelial cell recovery and function. <i>PLoS Pathogens</i> , 2018, 14, e1006806.	2.1	12
178	The role of CD32 during HIV-1 infection. <i>Nature</i> , 2018, 561, E17-E19.	18.7	43
179	Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. <i>Journal of Clinical Investigation</i> , 2018, 128, 1903-1912.	3.9	52
180	Viral protein Nef is detected in plasma of half of HIV-infected adults with undetectable plasma HIV RNA. <i>PLoS ONE</i> , 2018, 13, e0191613.	1.1	76

#	ARTICLE	IF	CITATIONS
181	Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. <i>PLoS Pathogens</i> , 2018, 14, e1006856.	2.1	70
182	Maximising the global health impact of future HIV cure-related interventions through advance planning. <i>Journal of Virus Eradication</i> , 2018, 4, 182-185.	0.3	2
183	Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication <i>In Vitro</i> and Modulate HIV Restriction Factor Expression. <i>Journal of Virology</i> , 2017, 91, .	1.5	33
184	Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. <i>Scientific Reports</i> , 2017, 7, 40354.	1.6	65
185	Mucosal Microbes Mitigate Maladies. <i>Immunity</i> , 2017, 46, 1-3.	6.6	7
186	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. <i>Lancet HIV</i> , 2017, 4, e251-e259.	2.1	10
187	A humanized mouse-based HIV-1 viral outgrowth assay with higher sensitivity than in vitro qVOA in detecting latently infected cells from individuals on ART with undetectable viral loads. <i>Virology</i> , 2017, 507, 135-139.	1.1	43
188	High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay. <i>EBioMedicine</i> , 2017, 20, 217-229.	2.7	50
189	HIV Antibody Level as a Marker of HIV Persistence and Low-Level Viral Replication. <i>Journal of Infectious Diseases</i> , 2017, 216, 72-81.	1.9	38
190	Signature of the Sleeper Cell: A Biomarker of HIV Latency Revealed. <i>Trends in Immunology</i> , 2017, 38, 457-458.	2.9	10
191	Preservation of Peripheral T Follicular Helper Cell Function in HIV Controllers. <i>Journal of Virology</i> , 2017, 91, .	1.5	32
192	SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency. <i>Cell Host and Microbe</i> , 2017, 21, 569-579.e6.	5.1	78
193	Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 215, 911-919.	1.9	95
194	Association of HIV-1 Gag-Specific IgG Antibodies With Natural Control of HIV-1 Infection in Individuals Not Carrying HLA-B*57:01 Is Only Observed in Viremic Controllers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, e90-e92.	0.9	12
195	Measuring the Size of the Latent Human Immunodeficiency Virus Reservoir: The Present and Future of Evaluating Eradication Strategies. <i>Journal of Infectious Diseases</i> , 2017, 215, S134-S141.	1.9	39
196	Ultrarapid Measurement of Diagnostic Antibodies by Magnetic Capture of Immune Complexes. <i>Scientific Reports</i> , 2017, 7, 3818.	1.6	10
197	Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 658-667.	0.5	22
198	Association of Arterial and Lymph Node Inflammation With Distinct Inflammatory Pathways in Human Immunodeficiency Virus Infection. <i>JAMA Cardiology</i> , 2017, 2, 163.	3.0	50

#	ARTICLE	IF	CITATIONS
199	Psoriasis risk SNPs and their association with HIV-1 control. <i>Human Immunology</i> , 2017, 78, 179-184.	1.2	10
200	Defining total-body AIDS-virus burden with implications for curative strategies. <i>Nature Medicine</i> , 2017, 23, 1271-1276.	15.2	322
201	An Optimized and Validated Method for Isolation and Characterization of Lymphocytes from HIV+ Human Gut Biopsies. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, S-31-S-39.	0.5	23
202	Identification of Genetically Intact HIV-1 Proviruses in Specific CD4 + T Cells from Effectively Treated Participants. <i>Cell Reports</i> , 2017, 21, 813-822.	2.9	304
203	Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection. <i>Journal of Virology</i> , 2017, 91, .	1.5	39
204	HLA-B*14:02-Restricted Env-Specific CD8 + T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection. <i>Journal of Virology</i> , 2017, 91, .	1.5	14
205	Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	1.3	21
206	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. <i>Clinical Infectious Diseases</i> , 2017, 65, 636-643.	2.9	67
207	High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 234-245.	0.5	3
208	Predominance of weakly cytotoxic, T-bet ^{Low} Eomes ^{Neg} CD8 ⁺ T-cells in human gastrointestinal mucosa: implications for HIV infection. <i>Mucosal Immunology</i> , 2017, 10, 1008-1020.	2.7	28
209	Comparison of cross-sectional HIV incidence assay results from dried blood spots and plasma. <i>PLoS ONE</i> , 2017, 12, e0172283.	1.1	17
210	Terminal differentiation of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls. <i>PLoS ONE</i> , 2017, 12, e0183357.	1.1	34
211	Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers. <i>Retrovirology</i> , 2017, 14, 41.	0.9	22
212	T-bet ⁺ B cells are induced by human viral infections and dominate the HIV gp140 response. <i>JCI Insight</i> , 2017, 2, .	2.3	164
213	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. <i>PLoS Medicine</i> , 2017, 14, e1002417.	3.9	186
214	The end of HIV: Still a very long way to go, but progress continues. <i>PLoS Medicine</i> , 2017, 14, e1002466.	3.9	14
215	Trans-Activation Response Element RNA is Detectable in the Plasma of a Subset of Aviremic HIV-1 ⁺ Infected Patients. <i>Acta Chimica Slovenica</i> , 2017, 64, 530-536.	0.2	11
216	A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals. <i>Pathogens and Immunity</i> , 2017, 2, 310.	1.4	10

#	ARTICLE	IF	CITATIONS
217	The interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure?. <i>Journal of Clinical Investigation</i> , 2016, 127, 103-105.	3.9	29
218	Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy. <i>PLoS ONE</i> , 2016, 11, e0155100.	1.1	150
219	Endothelin-1 Predicts Hemodynamically Assessed Pulmonary Arterial Hypertension in HIV Infection. <i>PLoS ONE</i> , 2016, 11, e0146355.	1.1	14
220	p16INK4a Expression and Immunologic Aging in Chronic HIV Infection. <i>PLoS ONE</i> , 2016, 11, e0166759.	1.1	10
221	Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. <i>PLoS Pathogens</i> , 2016, 12, e1005381.	2.1	37
222	International AIDS Society global scientific strategy: towards an HIV cure 2016. <i>Nature Medicine</i> , 2016, 22, 839-850.	15.2	395
223	Persistence of integrated HIV DNA in CXCR3+CCR6+ memory CD4+ T cells in HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , 2016, 30, 1511-1520.	1.0	68
224	Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 206-213.	0.9	95
225	Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy. <i>Aids</i> , 2016, 30, 2065-2074.	1.0	79
226	Reverse geroscience: how does exposure to early diseases accelerate the age-related decline in health?. <i>Annals of the New York Academy of Sciences</i> , 2016, 1386, 30-44.	1.8	24
227	Role of T-Cell Dysfunction, Inflammation, and Coagulation in Microvascular Disease in HIV. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	50
228	When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 214-221.	0.9	22
229	T-Cell Activation Independently Associates With Immune Senescence in HIV-Infected Recipients of Long-term Antiretroviral Treatment. <i>Journal of Infectious Diseases</i> , 2016, 214, 216-225.	1.9	97
230	Immune Activation and HIV-Specific CD8+ T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 791-800.	0.5	11
231	HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent PCSK9-Lipid Paradox. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	36
232	Defective proviruses rapidly accumulate during acute HIV-1 infection. <i>Nature Medicine</i> , 2016, 22, 1043-1049.	15.2	605
233	The Benefits of Early Antiretroviral Therapy for HIV Infection: How Early is Early Enough?. <i>EBioMedicine</i> , 2016, 11, 7-8.	2.7	10
234	Multiple Origins of Virus Persistence during Natural Control of HIV Infection. <i>Cell</i> , 2016, 166, 1004-1015.	13.5	156

#	ARTICLE	IF	CITATIONS
235	New insights into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy. <i>Retrovirology</i> , 2016, 13, 59.	0.9	90
236	Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw189.	0.4	72
237	Persistent HIV-1 replication during antiretroviral therapy. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 417-423.	1.5	133
238	Immunologic profiles distinguish aviremic HIV-infected adults. <i>Aids</i> , 2016, 30, 1553-1562.	1.0	22
239	Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa. <i>Journal of Infectious Diseases</i> , 2016, 214, 73-79.	1.9	13
240	Post-Treatment Controllers: Role in HIV "Cure" Research. <i>Current HIV/AIDS Reports</i> , 2016, 13, 1-9.	1.1	31
241	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , 2016, 45, 2038-2049.	0.9	43
242	HIV reservoirs: what, where and how to target them. <i>Nature Reviews Microbiology</i> , 2016, 14, 55-60.	13.6	259
243	Cerebral vasoreactivity is impaired in treated, virally suppressed HIV-infected individuals. <i>Aids</i> , 2016, 30, 45-55.	1.0	23
244	Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy. <i>PLoS ONE</i> , 2016, 11, e0160192.	1.1	26
245	HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects. <i>PLoS ONE</i> , 2016, 11, e0160341.	1.1	7
246	TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005349.	2.1	271
247	Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation. <i>PLoS Pathogens</i> , 2016, 12, e1005677.	2.1	78
248	CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. <i>PLoS Pathogens</i> , 2016, 12, e1005761.	2.1	350
249	A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. <i>EBioMedicine</i> , 2015, 2, 874-883.	2.7	242
250	HIV infection. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15035.	18.1	340
251	Geriatric Syndromes in Older HIV-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 161-167.	0.9	192
252	Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ 32. <i>Aids</i> , 2015, 29, 867-876.	1.0	26

#	ARTICLE	IF	CITATIONS
253	Lack of Evidence for Molecular Mimicry in HIV-Infected Subjects. <i>PLoS ONE</i> , 2015, 10, e0127662.	1.1	1
254	Mitral Annular and Coronary Artery Calcification Are Associated with Mortality in HIV-Infected Individuals. <i>PLoS ONE</i> , 2015, 10, e0130592.	1.1	4
255	CD8 ⁺ T-Cells Count in Acute Myocardial Infarction in HIV Disease in a Predominantly Male Cohort. <i>BioMed Research International</i> , 2015, 2015, 1-5.	0.9	17
256	The HIV cure research agenda: the role of mathematical modelling and cost-effectiveness analysis. <i>Journal of Virus Eradication</i> , 2015, 1, 245-249.	0.3	12
257	CD4/CD8 ratio: an emerging biomarker for HIV. <i>Lancet HIV</i> , 2015, 2, e76-e77.	2.1	31
258	Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. <i>Lancet HIV</i> , 2015, 2, e520-e529.	2.1	213
259	High Transmissibility During Early HIV Infection Among Men Who Have Sex With Men—San Francisco, California: Table 1.. <i>Journal of Infectious Diseases</i> , 2015, 211, 1757-1760.	1.9	23
260	Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. <i>Nature</i> , 2015, 517, 381-385.	13.7	469
261	Lymphoid Fibrosis Occurs in Long-Term Nonprogressors and Persists With Antiretroviral Therapy but May Be Reversible With Curative Interventions. <i>Journal of Infectious Diseases</i> , 2015, 211, 1068-1075.	1.9	49
262	Soluble T Cell Immunoglobulin Mucin Domain 3 Is Shed from CD8 ⁺ T Cells by the Sheddase ADAM10, Is Increased in Plasma during Untreated HIV Infection, and Correlates with HIV Disease Progression. <i>Journal of Virology</i> , 2015, 89, 3723-3736.	1.5	71
263	Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial. <i>Lancet HIV</i> , 2015, 2, e82-e91.	2.1	34
264	Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy. <i>Journal of Infectious Diseases</i> , 2015, 212, 596-607.	1.9	138
265	Novel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals. <i>JACC: Heart Failure</i> , 2015, 3, 591-599.	1.9	65
266	Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell—Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification. <i>Journal of Immunology</i> , 2015, 194, 5320-5328.	0.4	29
267	CD4 ⁺ T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa. <i>International Journal of Epidemiology</i> , 2015, 44, 251-263.	0.9	10
268	Gut epithelial barrier and systemic inflammation during chronic HIV infection. <i>Aids</i> , 2015, 29, 43-51.	1.0	156
269	Select host restriction factors are associated with HIV persistence during antiretroviral therapy. <i>Aids</i> , 2015, 29, 411-420.	1.0	54
270	Virome analysis of antiretroviral-treated HIV patients shows no correlation between T-cell activation and anelloviruses levels. <i>Journal of Clinical Virology</i> , 2015, 72, 106-113.	1.6	26

#	ARTICLE	IF	CITATIONS
271	Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4762-71.	3.3	48
272	End-Stage Renal Disease Among HIV-Infected Adults in North America. <i>Clinical Infectious Diseases</i> , 2015, 60, 941-949.	2.9	142
273	The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis. <i>Journal of Virus Eradication</i> , 2015, 1, 245-249.	0.3	7
274	Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration. <i>PLoS ONE</i> , 2014, 9, e85516.	1.1	34
275	Impact of HIV on CD8+ T Cell CD57 Expression Is Distinct from That of CMV and Aging. <i>PLoS ONE</i> , 2014, 9, e89444.	1.1	85
276	Towards an HIV cure. <i>Journal of the International AIDS Society</i> , 2014, 17, 19479.	1.2	8
277	Cutting Edge: An Antibody Recognizing Ancestral Endogenous Virus Glycoproteins Mediates Antibody-Dependent Cellular Cytotoxicity on HIV-1 Infected Cells. <i>Journal of Immunology</i> , 2014, 193, 1544-1548.	0.4	21
278	Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection. <i>Journal of Infectious Diseases</i> , 2014, 210, 1228-1238.	1.9	395
279	Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Non-AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment. <i>Journal of Infectious Diseases</i> , 2014, 210, 1248-1259.	1.9	464
280	Limited HIV Infection of Central Memory and Stem Cell Memory CD4+ T Cells Is Associated with Lack of Progression in Viremic Individuals. <i>PLoS Pathogens</i> , 2014, 10, e1004345.	2.1	76
281	Disparities in the Quality of HIV Care When Using US Department of Health and Human Services Indicators. <i>Clinical Infectious Diseases</i> , 2014, 58, 1185-1189.	2.9	65
282	HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality. <i>PLoS Pathogens</i> , 2014, 10, e1004078.	2.1	495
283	LILRB2 Interaction with HLA Class I Correlates with Control of HIV-1 Infection. <i>PLoS Genetics</i> , 2014, 10, e1004196.	1.5	83
284	Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy. <i>PLoS Pathogens</i> , 2014, 10, e1004473.	2.1	437
285	Reply to Karch et al. <i>Journal of Infectious Diseases</i> , 2014, 210, 159-160.	1.9	0
286	The Kynurenine Pathway of Tryptophan Catabolism, CD4+ T-Cell Recovery, and Mortality Among HIV-Infected Ugandans Initiating Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2014, 210, 383-391.	1.9	101
287	Discordance Between Peripheral and Colonic Markers of Inflammation During Suppressive ART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 133-141.	0.9	23
288	A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells. <i>Aids</i> , 2014, 28, 439-442.	1.0	62

#	ARTICLE	IF	CITATIONS
289	Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1. <i>Aids</i> , 2014, 28, 317-323.	1.0	25
290	HIV Prevention and Treatment Fields Join Forces. <i>EBioMedicine</i> , 2014, 1, 4-5.	2.7	2
291	A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2014, 58, 883-890.	2.9	166
292	Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease. <i>Aids</i> , 2014, 28, 1749-1758.	1.0	101
293	Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. <i>Aids</i> , 2014, 28, 1791-1796.	1.0	25
294	A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans. <i>Aids</i> , 2014, 28, 1289-1295.	1.0	36
295	A closer look at hepatitis C clearance in HIV controllers. <i>Aids</i> , 2014, 28, 1241-1242.	1.0	3
296	Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection. <i>Retrovirology</i> , 2014, 11, 10.	0.9	43
297	Sevelamer Does Not Decrease Lipopolysaccharide or Soluble CD14 Levels But Decreases Soluble Tissue Factor, Low-Density Lipoprotein (LDL) Cholesterol, and Oxidized LDL Cholesterol Levels in Individuals With Untreated HIV Infection. <i>Journal of Infectious Diseases</i> , 2014, 210, 1549-1554.	1.9	80
298	Effects of Alpha Interferon Treatment on Intrinsic Anti-HIV-1 Immunity <i>in Vivo</i> . <i>Journal of Virology</i> , 2014, 88, 763-767.	1.5	29
299	Reduction of HIV Persistence Following Transplantation in HIV-Infected Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2014, 14, 1136-1141.	2.6	57
300	Galectin-9 Is Rapidly Released During Acute HIV-1 Infection and Remains Sustained at High Levels Despite Viral Suppression Even in Elite Controllers. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 654-664.	0.5	78
301	Decreased HIV Type 1 Transcription in CCR5- Δ 32 Heterozygotes During Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2014, 210, 1838-1843.	1.9	11
302	The CD8 ⁺ Memory Stem T Cell (T _{SCM}) Subset Is Associated with Improved Prognosis in Chronic HIV-1 Infection. <i>Journal of Virology</i> , 2014, 88, 13836-13844.	1.5	53
303	Exogenous and endogenous hyaluronic acid reduces HIV infection of CD4 + T cells. <i>Immunology and Cell Biology</i> , 2014, 92, 770-780.	1.0	15
304	Towards a cure for HIV—are we making progress?. <i>Lancet</i> , The, 2014, 384, 209-211.	6.3	25
305	Antiretroviral therapy: stubborn limitations persist. <i>Lancet</i> , The, 2014, 384, 214-216.	6.3	2
306	HIV Antibody Characterization as a Method to Quantify Reservoir Size During Curative Interventions. <i>Journal of Infectious Diseases</i> , 2014, 209, 1613-1617.	1.9	48

#	ARTICLE	IF	CITATIONS
307	Immunologic strategies for HIV-1 remission and eradication. <i>Science</i> , 2014, 345, 169-174.	6.0	193
308	Lymphoma Immune Reconstitution Inflammatory Syndrome in the Center for AIDS Research Network of Integrated Clinical Systems Cohort. <i>Clinical Infectious Diseases</i> , 2014, 59, 279-286.	2.9	35
309	Low Proportions of CD28 ^{hi} CD8 ⁺ T cells Expressing CD57 Can Be Reversed by Early ART Initiation and Predict Mortality in Treated HIV Infection. <i>Journal of Infectious Diseases</i> , 2014, 210, 374-382.	1.9	53
310	Dependence on the CCR5 Coreceptor for Viral Replication Explains the Lack of Rebound of CXCR4-Predicted HIV Variants in the Berlin Patient. <i>Clinical Infectious Diseases</i> , 2014, 59, 596-600.	2.9	35
311	Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4 ⁺ T cell recovery after the initiation of antiretroviral therapy for HIV disease. <i>AIDS Research and Therapy</i> , 2014, 11, 27.	0.7	2
312	Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection. <i>Aids</i> , 2014, 28, 511-519.	1.0	37
313	Composition and Function of T Cell Subpopulations Are Slow to Change Despite Effective Antiretroviral Treatment of HIV Disease. <i>PLoS ONE</i> , 2014, 9, e85613.	1.1	41
314	Regulatory B Cells Inhibit Cytotoxic T Lymphocyte (CTL) Activity and Elimination of Infected CD4 T Cells after In Vitro Reactivation of HIV Latent Reservoirs. <i>PLoS ONE</i> , 2014, 9, e92934.	1.1	34
315	CD4 ⁺ and CD8 ⁺ T Cell Activation Are Associated with HIV DNA in Resting CD4 ⁺ T Cells. <i>PLoS ONE</i> , 2014, 9, e110731.	1.1	88
316	The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4 ⁺ T Cell Recovery: A Randomized Crossover Trial. <i>PLoS ONE</i> , 2014, 9, e116306.	1.1	56
317	Biomarker reveals HIV's hidden reservoir. <i>ELife</i> , 2014, 3, e04742.	2.8	5
318	Dysbiosis of the Gut Microbiota Is Associated with HIV Disease Progression and Tryptophan Catabolism. <i>Science Translational Medicine</i> , 2013, 5, 193ra91.	5.8	578
319	Systemic Effects of Inflammation on Health during Chronic HIV Infection. <i>Immunity</i> , 2013, 39, 633-645.	6.6	651
320	Elevated levels of asymmetric dimethylarginine are associated with lower CD4 ⁺ count and higher viral load in HIV-infected individuals. <i>Atherosclerosis</i> , 2013, 229, 246-252.	0.4	20
321	Antibodies advance the search for a cure. <i>Nature</i> , 2013, 503, 207-208.	13.7	6
322	The end of AIDS: HIV infection as a chronic disease. <i>Lancet</i> , The, 2013, 382, 1525-1533.	6.3	1,428
323	The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4987-96.	3.3	260
324	CD56 ^{neg} CD16 ⁺ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. <i>Retrovirology</i> , 2013, 10, 158.	0.9	104

#	ARTICLE	IF	CITATIONS
325	Immune activation and HIV persistence: implications for curative approaches to HIV infection. <i>Immunological Reviews</i> , 2013, 254, 326-342.	2.8	334
326	Influence of HLA-C Expression Level on HIV Control. <i>Science</i> , 2013, 340, 87-91.	6.0	352
327	Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. <i>Lancet, The</i> , 2013, 381, 2109-2117.	6.3	275
328	Short Communication: HIV+ Viremic Slow Progressors Maintain Low Regulatory T Cell Numbers in Rectal Mucosa but Exhibit High T Cell Activation. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 172-177.	0.5	13
329	Expression profile of host restriction factors in HIV-1 elite controllers. <i>Retrovirology</i> , 2013, 10, 106.	0.9	79
330	Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size. <i>Journal of Infectious Diseases</i> , 2013, 208, 1202-1211.	1.9	285
331	The Distribution of HIV DNA and RNA in Cell Subsets Differs in Gut and Blood of HIV-Positive Patients on ART: Implications for Viral Persistence. <i>Journal of Infectious Diseases</i> , 2013, 208, 1212-1220.	1.9	154
332	Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2013, 208, 1240-1249.	1.9	43
333	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001-2009. <i>Clinical Infectious Diseases</i> , 2013, 56, 1174-1182.	2.9	90
334	Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers. <i>Aids</i> , 2013, 27, 2691-2696.	1.0	9
335	T Cells Target APOBEC3 Proteins in Human Immunodeficiency Virus Type 1-Infected Humans and Simian Immunodeficiency Virus-Infected Indian Rhesus Macaques. <i>Journal of Virology</i> , 2013, 87, 6073-6080.	1.5	6
336	Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient. <i>PLoS Pathogens</i> , 2013, 9, e1003347.	2.1	244
337	Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers. <i>PLoS Pathogens</i> , 2013, 9, e1003691.	2.1	94
338	Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration. <i>Journal of Infectious Diseases</i> , 2013, 207, 213-222.	1.9	183
339	Cell-Based Measures of Viral Persistence Are Associated With Immune Activation and Programmed Cell Death Protein 1 (PD-1) Expressing CD4+ T cells. <i>Journal of Infectious Diseases</i> , 2013, 208, 50-56.	1.9	227
340	Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies. <i>PLoS Pathogens</i> , 2013, 9, e1003174.	2.1	524
341	Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls. <i>PLoS Pathogens</i> , 2013, 9, e1003515.	2.1	109
342	AIDS Alters the Commensal Plasma Virome. <i>Journal of Virology</i> , 2013, 87, 10912-10915.	1.5	89

#	ARTICLE	IF	CITATIONS
343	Increase in 2â€™Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial. <i>Journal of Infectious Diseases</i> , 2013, 208, 1436-1442.	1.9	151
344	The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. <i>Blood</i> , 2013, 121, 4635-4646.	0.6	117
345	Temporal Trends in Presentation and Survival for HIV-Associated Lymphoma in the Antiretroviral Therapy Era. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1221-1229.	3.0	152
346	Preclinical Evaluation of HIV Eradication Strategies in the Simian Immunodeficiency Virus-Infected Rhesus Macaque: A Pilot Study Testing Inhibition of Indoleamine 2,3-Dioxygenase. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 207-214.	0.5	16
347	Genetic interplay between <i>HLA-C</i> and <i>MIR148A</i> in HIV control and Crohn disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 20705-20710.	3.3	109
348	Roadblocks to translational challenges on viral pathogenesis. <i>Nature Medicine</i> , 2013, 19, 30-34.	15.2	7
349	Association of HLA-DRB1â€™restricted CD4+ T cell responses with HIV immune control. <i>Nature Medicine</i> , 2013, 19, 930-933.	15.2	88
350	Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. <i>Blood</i> , 2013, 121, 1124-1135.	0.6	347
351	Response: maraviroc intensification and microbial translocation. <i>Blood</i> , 2013, 122, 2283-2284.	0.6	5
352	Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers. <i>Aids</i> , 2013, 27, 2255-2260.	1.0	44
353	The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy. <i>Aids</i> , 2013, 27, 2101-2110.	1.0	18
354	Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 149-163.	0.9	188
355	Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. <i>Aids</i> , 2013, 27, 973-979.	1.0	315
356	Cortisol Patterns Are Associated with T Cell Activation in HIV. <i>PLoS ONE</i> , 2013, 8, e63429.	1.1	31
357	Higher CD27+CD8+ T Cells Percentages during Suppressive Antiretroviral Therapy Predict Greater Subsequent CD4+ T Cell Recovery in Treated HIV Infection. <i>PLoS ONE</i> , 2013, 8, e84091.	1.1	9
358	Unmasking Lymphoma Immune Reconstitution Inflammatory Syndrome Among HIV-Infected Individuals In The Center For AIDS Research Network Of Integrated Clinical Systems. <i>Blood</i> , 2013, 122, 4331-4331.	0.6	1
359	Gag-Positive Reservoir Cells Are Susceptible to HIV-Specific Cytotoxic T Lymphocyte Mediated Clearance In Vitro and Can Be Detected In Vivo. <i>PLoS ONE</i> , 2013, 8, e71879.	1.1	51
360	Increased CD34 ⁺ /KDR ⁺ cells are not associated with carotid artery intima-media thickness progression in chronic HIV-positive subjects. <i>Antiviral Therapy</i> , 2012, 17, 557-563.	0.6	22

#	ARTICLE	IF	CITATIONS
361	CD28-Negative CD4+ and CD8+ T Cells in Antiretroviral Therapy—Naive HIV-Infected Adults Enrolled in Adult Clinical Trials Group Studies. <i>Journal of Infectious Diseases</i> , 2012, 205, 1730-1738.	1.9	31
362	Psoriasis Patients Are Enriched for Genetic Variants That Protect against HIV-1 Disease. <i>PLoS Genetics</i> , 2012, 8, e1002514.	1.5	66
363	Plasma HIV-1 RNA Levels During Antiretroviral Therapy: How Low Is Low Enough?. <i>Clinical Infectious Diseases</i> , 2012, 54, 733-735.	2.9	16
364	Cytomegalovirus Immunoglobulin G Antibody Is Associated With Subclinical Carotid Artery Disease Among HIV-Infected Women. <i>Journal of Infectious Diseases</i> , 2012, 205, 1788-1796.	1.9	100
365	Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers. <i>Aids</i> , 2012, 26, 1869-1878.	1.0	63
366	The Effect of a "Universal Antiretroviral Therapy" Recommendation on HIV RNA Levels Among HIV-Infected Patients Entering Care With a CD4 Count Greater Than 500/ÅL in a Public Health Setting. <i>Clinical Infectious Diseases</i> , 2012, 55, 1690-1697.	2.9	28
367	HIV Infection Is Associated With Decreased Thrombin Generation. <i>Clinical Infectious Diseases</i> , 2012, 54, 1196-1203.	2.9	22
368	Prevalence and Significance of HIV-1 Drug Resistance Mutations among Patients on Antiretroviral Therapy with Detectable Low-Level Viremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5998-6000.	1.4	56
369	Carotid Intima—Media Thickness Progression in HIV—Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. <i>Journal of the American Heart Association</i> , 2012, 1, .	1.6	87
370	Immune Activation in the Pathogenesis of Treated Chronic HIV Disease: A Workshop Summary. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 469-477.	0.5	62
371	Immunologic Basis of Cardiovascular Disease in HIV-Infected Adults. <i>Journal of Infectious Diseases</i> , 2012, 205, S375-S382.	1.9	228
372	HIV Status, Burden of Comorbid Disease, and Biomarkers of Inflammation, Altered Coagulation, and Monocyte Activation. <i>Clinical Infectious Diseases</i> , 2012, 55, 126-136.	2.9	221
373	Does an Index Composed of Clinical Data Reflect Effects of Inflammation, Coagulation, and Monocyte Activation on Mortality Among Those Aging With HIV?. <i>Clinical Infectious Diseases</i> , 2012, 54, 984-994.	2.9	197
374	Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. <i>Aids</i> , 2012, 26, 1967-1969.	1.0	31
375	A Randomized Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 317-325.	0.9	36
376	Association of tenofovir exposure with kidney disease risk in HIV infection. <i>Aids</i> , 2012, 26, 867-875.	1.0	347
377	A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. <i>Aids</i> , 2012, 26, 805-814.	1.0	83
378	HIV and Aging. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, S1-S18.	0.9	474

#	ARTICLE	IF	CITATIONS
379	The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. <i>Aids</i> , 2012, 26, 1115-1120.	1.0	70
380	Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. <i>Blood</i> , 2012, 119, 745-755.	0.6	38
381	Blood T-cell receptor diversity decreases during the course of HIV infection, but the potential for a diverse repertoire persists. <i>Blood</i> , 2012, 119, 3469-3477.	0.6	36
382	HIV infection, lymphoid fibrosis, and disease. <i>Blood</i> , 2012, 120, 1753-1754.	0.6	7
383	Case 30-2012. <i>New England Journal of Medicine</i> , 2012, 367, 1246-1254.	13.9	2
384	Hematopoietic-Stem-Cell-Based Gene Therapy for HIV Disease. <i>Cell Stem Cell</i> , 2012, 10, 137-147.	5.2	110
385	Epistatic interactions between Fc (GM) and Fc γ R genes and the host control of human immunodeficiency virus replication. <i>Human Immunology</i> , 2012, 73, 263-266.	1.2	21
386	Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. <i>Human Molecular Genetics</i> , 2012, 21, 4334-4347.	1.4	61
387	Immunosenescence and HIV. <i>Current Opinion in Immunology</i> , 2012, 24, 501-506.	2.4	126
388	Influence of HAART on Alternative Reading Frame Immune Responses over the Course of HIV-1 Infection. <i>PLoS ONE</i> , 2012, 7, e39311.	1.1	17
389	Human Endogenous Retrovirus Expression Is Inversely Associated with Chronic Immune Activation in HIV-1 Infection. <i>PLoS ONE</i> , 2012, 7, e41021.	1.1	26
390	Differential Expression of CD96 Surface Molecule Represents CD8+ T Cells with Dissimilar Effector Function during HIV-1 Infection. <i>PLoS ONE</i> , 2012, 7, e51696.	1.1	15
391	Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells. <i>Science Translational Medicine</i> , 2012, 4, 132ra53.	5.8	555
392	Towards an HIV cure: a global scientific strategy. <i>Nature Reviews Immunology</i> , 2012, 12, 607-614.	10.6	485
393	Towards a cure for HIV. <i>Nature</i> , 2012, 487, 293-294.	13.7	23
394	Shock and kill. <i>Nature</i> , 2012, 487, 439-440.	13.7	525
395	Carotid Intima-Media Thickness Among Human Immunodeficiency Virus-Infected Patients Without Coronary Calcium. <i>American Journal of Cardiology</i> , 2012, 109, 742-747.	0.7	46
396	Lack of Evidence for mtDNA as a Biomarker of Innate Immune Activation in HIV Infection. <i>PLoS ONE</i> , 2012, 7, e50486.	1.1	14

#	ARTICLE	IF	CITATIONS
397	Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. <i>Blood</i> , 2011, 117, 3799-3808.	0.6	146
398	Breaking Free of Sample Size Dogma to Perform Innovative Translational Research. <i>Science Translational Medicine</i> , 2011, 03, 87ps24.	5.8	122
399	Host Response to Translocated Microbial Products Predicts Outcomes of Patients With HBV or HCV Infection. <i>Gastroenterology</i> , 2011, 141, 1220-1230.e3.	0.6	268
400	How to escape treatment. <i>Nature</i> , 2011, 477, 36-37.	13.7	15
401	HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. <i>Blood</i> , 2011, 117, 5142-5151.	0.6	140
402	HIV Infection, Inflammation, Immunosenescence, and Aging. <i>Annual Review of Medicine</i> , 2011, 62, 141-155.	5.0	1,109
403	T cell activation predicts carotid artery stiffness among HIV-infected women. <i>Atherosclerosis</i> , 2011, 217, 207-213.	0.4	117
404	A Low T Regulatory Cell Response May Contribute to Both Viral Control and Generalized Immune Activation in HIV Controllers. <i>PLoS ONE</i> , 2011, 6, e15924.	1.1	122
405	Retention in Care and Connection to Care among HIV-Infected Patients on Antiretroviral Therapy in Africa: Estimation via a Sampling-Based Approach. <i>PLoS ONE</i> , 2011, 6, e21797.	1.1	81
406	Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. <i>Aids</i> , 2011, 25, 2123-2131.	1.0	195
407	Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. <i>Aids</i> , 2011, 25, 1813-1822.	1.0	140
408	N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. <i>Aids</i> , 2011, 25, 651-657.	1.0	29
409	HIV disease progression correlates with the generation of dysfunctional naive CD8low T cells. <i>Blood</i> , 2011, 117, 2189-2199.	0.6	30
410	Differential microRNA regulation of HLA-C expression and its association with HIV control. <i>Nature</i> , 2011, 472, 495-498.	13.7	328
411	Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter. <i>Journal of Virological Methods</i> , 2011, 175, 261-265.	1.0	7
412	Drug Effectiveness Explained: The Mathematics of Antiviral Agents for HIV. <i>Science Translational Medicine</i> , 2011, 3, 91ps30.	5.8	12
413	HIV-Specific CD4+ T Cells May Contribute to Viral Persistence in HIV Controllers. <i>Clinical Infectious Diseases</i> , 2011, 52, 681-687.	2.9	33
414	Valganciclovir Reduces T Cell Activation in HIV-Infected Individuals With Incomplete CD4+ T Cell Recovery on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 203, 1474-1483.	1.9	308

#	ARTICLE	IF	CITATIONS
415	Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection. <i>Journal of Infectious Diseases</i> , 2011, 203, 780-790.	1.9	957
416	A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response. <i>Journal of Infectious Diseases</i> , 2011, 203, 960-968.	1.9	176
417	Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America. <i>American Journal of Epidemiology</i> , 2011, 174, 727-735.	1.6	9
418	Increased Frequency of Regulatory T Cells Accompanies Increased Immune Activation in Rectal Mucosae of HIV-Positive Noncontrollers. <i>Journal of Virology</i> , 2011, 85, 11422-11434.	1.5	98
419	Association of Vitamin D Insufficiency with Carotid Intima-Media Thickness in HIV-Infected Persons. <i>Clinical Infectious Diseases</i> , 2011, 52, 941-944.	2.9	44
420	Viremia Copy-Years Predicts Mortality Among Treatment-Naive HIV-Infected Patients Initiating Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2011, 53, 927-935.	2.9	122
421	Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. <i>Aids</i> , 2011, 25, 1289-1298.	1.0	130
422	Strong Human Endogenous Retrovirus-Specific T Cell Responses Are Associated with Control of HIV-1 in Chronic Infection. <i>Journal of Virology</i> , 2011, 85, 6977-6985.	1.5	50
423	Reappraisal of the Relationship between the HIV-1-Protective Single-Nucleotide Polymorphism 35 Kilobases Upstream of the <i>HLA-C</i> Gene and Surface HLA-C Expression. <i>Journal of Virology</i> , 2011, 85, 3367-3374.	1.5	52
424	T Cell Activation and Senescence Predict Subclinical Carotid Artery Disease in HIV-Infected Women. <i>Journal of Infectious Diseases</i> , 2011, 203, 452-463.	1.9	281
425	Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. <i>Journal of Infectious Diseases</i> , 2011, 204, 893-901.	1.9	33
426	The Effect of AIDS Clinical Trials Group Protocol 5164 on the Time From <i>Pneumocystis jirovecii</i> Pneumonia Diagnosis to Antiretroviral Initiation in Routine Clinical Practice: A Case Study of Diffusion, Dissemination, and Implementation. <i>Clinical Infectious Diseases</i> , 2011, 53, 1008-1014.	2.9	9
427	Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes. <i>Journal of Infectious Diseases</i> , 2011, 203, 1174-1181.	1.9	125
428	Human Endogenous Retrovirus K106 (HERV-K106) Was Infectious after the Emergence of Anatomically Modern Humans. <i>PLoS ONE</i> , 2011, 6, e20234.	1.1	46
429	Immune Activation, Cd4+ T Cell Counts, and Viremia Exhibit Oscillatory Patterns over Time in Patients with Highly Resistant HIV Infection. <i>PLoS ONE</i> , 2011, 6, e21190.	1.1	12
430	HIV RNA level in early infection is predicted by viral load in the transmission source. <i>Aids</i> , 2010, 24, 941-945.	1.0	65
431	Biomarkers in HIV disease. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 459-462.	1.5	9
432	HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. <i>Aids</i> , 2010, 24, 1095-1105.	1.0	127

#	ARTICLE	IF	CITATIONS
433	Spending More to Save More: Interventions to Promote Adherence. <i>Annals of Internal Medicine</i> , 2010, 152, 54.	2.0	26
434	Correlating cellular and molecular signatures of mucosal immunity that distinguish HIV controllers from noncontrollers. <i>Blood</i> , 2010, 115, e20-e32.	0.6	36
435	When to Start Antiretroviral Therapy. <i>Current HIV/AIDS Reports</i> , 2010, 7, 60-68.	1.1	28
436	Effects of thymic selection of the T-cell repertoire on HLA class II-associated control of HIV infection. <i>Nature</i> , 2010, 465, 350-354.	13.7	269
437	Can HIV be cured with stem cell therapy?. <i>Nature Biotechnology</i> , 2010, 28, 807-810.	9.4	25
438	Cytomegalovirus-Specific T Cells Persist at Very High Levels during Long-Term Antiretroviral Treatment of HIV Disease. <i>PLoS ONE</i> , 2010, 5, e8886.	1.1	176
439	Transmitted Drug Resistance in Persons with Acute/Early HIV-1 in San Francisco, 2002-2009. <i>PLoS ONE</i> , 2010, 5, e15510.	1.1	64
440	How Do HIV Elite Controllers Do What They Do?. <i>Clinical Infectious Diseases</i> , 2010, 51, 239-241.	2.9	43
441	Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of T _H 17 to Regulatory T Cells in HIV Disease. <i>Science Translational Medicine</i> , 2010, 2, 32ra36.	5.8	454
442	HIV Controllers with HLA-DRB1*13 and HLA-DQB1*06 Alleles Have Strong, Polyfunctional Mucosal CD4 ⁺ T-Cell Responses. <i>Journal of Virology</i> , 2010, 84, 11020-11029.	1.5	102
443	Immunodominant HIV-Specific CD8 ⁺ T-Cell Responses Are Common to Blood and Gastrointestinal Mucosa, and Gag-Specific Responses Dominate in Rectal Mucosa of HIV Controllers. <i>Journal of Virology</i> , 2010, 84, 10354-10365.	1.5	61
444	Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2010, 50, 1512-1520.	2.9	187
445	Impact of HIV Infection on Diastolic Function and Left Ventricular Mass. <i>Circulation: Heart Failure</i> , 2010, 3, 132-139.	1.6	163
446	Association Between Kidney Function and Albuminuria With Cardiovascular Events in HIV-Infected Persons. <i>Circulation</i> , 2010, 121, 651-658.	1.6	153
447	Treatment-Mediated Alterations in HIV Fitness Preserve CD4 ⁺ T Cell Counts but Have Minimal Effects on Viral Load. <i>PLoS Computational Biology</i> , 2010, 6, e1001012.	1.5	19
448	Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation. <i>Aids</i> , 2010, 24, 1001-1005.	1.0	25
449	Initiation of antiretroviral therapy at higher nadir CD4 ⁺ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. <i>Aids</i> , 2010, 24, 1897-1905.	1.0	65
450	A Maraviroc-Resistant HIV-1 with Narrow Cross-Resistance to Other CCR5 Antagonists Depends on both N-Terminal and Extracellular Loop Domains of Drug-Bound CCR5. <i>Journal of Virology</i> , 2010, 84, 10863-10876.	1.5	100

#	ARTICLE	IF	CITATIONS
451	Antiretroviral therapy and management of HIV infection. <i>Lancet</i> , The, 2010, 376, 49-62.	6.3	348
452	The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. <i>Science</i> , 2010, 330, 1551-1557.	6.0	1,054
453	The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy. <i>PLoS ONE</i> , 2009, 4, e7196.	1.1	104
454	Characterization of Human Immunodeficiency Virus Type 1 Populations Containing CXCR4-Using Variants from Recently Infected Individuals. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 795-802.	0.5	40
455	Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviral-treated HIV Infection. <i>Journal of Infectious Diseases</i> , 2009, 199, 1177-1185.	1.9	527
456	In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Lamivudine. <i>Journal of Virology</i> , 2009, 83, 2038-2043.	1.5	76
457	Incomplete Peripheral CD4 ⁺ Cell Count Restoration in HIV-infected Patients Receiving Long-term Antiretroviral Treatment. <i>Clinical Infectious Diseases</i> , 2009, 48, 787-794.	2.9	329
458	Evidence for Persistent Low-Level Viremia in Individuals Who Control Human Immunodeficiency Virus in the Absence of Antiretroviral Therapy. <i>Journal of Virology</i> , 2009, 83, 329-335.	1.5	191
459	HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. <i>Aids</i> , 2009, 23, 2143-2149.	1.0	99
460	Cross-Sectional Dating of Novel Haplotypes of HERV-K 113 and HERV-K 115 Indicate These Proviruses Originated in Africa before <i>Homo sapiens</i> . <i>Molecular Biology and Evolution</i> , 2009, 26, 2617-2626.	3.5	34
461	Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. <i>Aids</i> , 2009, 23, 1059-1067.	1.0	324
462	CD4 ⁺ T Cell Recovery with Antiretroviral Therapy: More Than the Sum of the Parts. <i>Clinical Infectious Diseases</i> , 2009, 48, 362-364.	2.9	23
463	Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells. <i>Journal of Biological Chemistry</i> , 2009, 284, 6782-6789.	1.6	252
464	Transcriptional Errors in Human Immunodeficiency Virus Type 1 Generate Targets for T-Cell Responses. <i>Vaccine Journal</i> , 2009, 16, 1369-1371.	3.2	14
465	Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-experienced Patients with HIV Infection in North America. <i>Clinical Infectious Diseases</i> , 2009, 49, 1582-1590.	2.9	55
466	HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. <i>Nature Genetics</i> , 2009, 41, 1290-1294.	9.4	265
467	Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment. <i>Computational Statistics and Data Analysis</i> , 2009, 53, 766-775.	0.7	6
468	Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. <i>New England Journal of Medicine</i> , 2009, 360, 1815-1826.	13.9	986

#	ARTICLE	IF	CITATIONS
469	Delaying a Treatment Switch in Antiretroviral-Treated HIV Type 1-Infected Patients with Detectable Drug-Resistant Viremia Does Not Have a Profound Effect on Immune Parameters: AIDS Clinical Trials Group Study A5115. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 135-139.	0.5	6
470	HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. <i>BMJ: British Medical Journal</i> , 2009, 338, a3172-a3172.	2.4	579
471	Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression. <i>Aids</i> , 2009, 23, 1965-1970.	1.0	36
472	Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. <i>Aids</i> , 2009, 23, 2021-2027.	1.0	137
473	Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. <i>Blood</i> , 2009, 113, 3978-3989.	0.6	198
474	Reduced thymus activity and infection prematurely age the immune system. <i>Journal of Clinical Investigation</i> , 2009, 119, 2884-2887.	3.9	20
475	Human Herpesvirus Replication and Abnormal CD8+ T Cell Activation and Low CD4+ T Cell Counts in Antiretroviral-Suppressed HIV-Infected Patients. <i>PLoS ONE</i> , 2009, 4, e5277.	1.1	18
476	Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2009, 17, 118-23.	2.9	131
477	CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. <i>Nature Medicine</i> , 2008, 14, 413-420.	15.2	118
478	Raltegravir. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 117-118.	21.5	26
479	Relationship between T Cell Activation and CD4 ⁺ T Cell Count in HIV-Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy. <i>Journal of Infectious Diseases</i> , 2008, 197, 126-133.	1.9	579
480	Viral Dynamics and In Vivo Fitness of HIV-1 in the Presence and Absence of Enfuvirtide. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 572-576.	0.9	20
481	HLA Class I-Restricted T-Cell Responses May Contribute to the Control of Human Immunodeficiency Virus Infection, but Such Responses Are Not Always Necessary for Long-Term Virus Control. <i>Journal of Virology</i> , 2008, 82, 5398-5407.	1.5	200
482	HIV-Induced Changes in T Cell Signaling Pathways. <i>Journal of Immunology</i> , 2008, 180, 6490-6500.	0.4	35
483	Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. <i>Aids</i> , 2008, 22, 825-833.	1.0	107
484	Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. <i>Aids</i> , 2008, 22, 2097-2106.	1.0	105
485	Antiretroviral Treatment Effect on Immune Activation Reduces Cerebrospinal Fluid HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 544-552.	0.9	52
486	Not All Missed Doses Are the Same: Sustained NNRTI Treatment Interruptions Predict HIV Rebound at Low-to-Moderate Adherence Levels. <i>PLoS ONE</i> , 2008, 3, e2783.	1.1	174

#	ARTICLE	IF	CITATIONS
487	Clinical Implications of HIV Fitness and Virulence. , 2008, , 161-169.		0
488	Transmitted Minority Drug-Resistant HIV Variants: A New Epidemic?. PLoS Medicine, 2008, 5, e164.	3.9	10
489	Enfuvirtide Cerebrospinal Fluid (CSF) Pharmacokinetics and Potential use in Defining CSF HIV-1 Origin. Antiviral Therapy, 2008, 13, 369-374.	0.6	27
490	Comparison of an Interferon- γ Release Assay with Tuberculin Skin Testing in HIV-infected Individuals. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 737-742.	2.5	185
491	Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility of Human Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors. Journal of Virology, 2007, 81, 3240-3250.	1.5	68
492	History-adjusted Marginal Structural Models for Estimating Time-varying Effect Modification. American Journal of Epidemiology, 2007, 166, 985-993.	1.6	47
493	Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). International Journal of Epidemiology, 2007, 36, 294-301.	0.9	176
494	Presenting Plasma HIV RNA Level and Rate of CD4 T-Cell Decline—Reply. JAMA - Journal of the American Medical Association, 2007, 297, 805.	3.8	0
495	Interruption of Enfuvirtide in HIV-1 Infected Adults with Incomplete Viral Suppression on an Enfuvirtide-Based Regimen. Journal of Infectious Diseases, 2007, 195, 387-391.	1.9	41
496	Partial treatment interruptions. Current Opinion in HIV and AIDS, 2007, 2, 46-55.	1.5	3
497	A new approach for “deep salvage” trials in advanced HIV infection. Aids, 2007, 21, 1503-1506.	1.0	8
498	Dysfunctional natural killer cells, in vivo, are governed by HIV viremia regardless of whether the infected individual is on antiretroviral therapy. Aids, 2007, 21, 2363-2365.	1.0	31
499	Human Immunodeficiency Virus Controllers: Mechanisms of Durable Virus Control in the Absence of Antiretroviral Therapy. Immunity, 2007, 27, 406-416.	6.6	646
500	Individualized treatment rules: Generating candidate clinical trials. Statistics in Medicine, 2007, 26, 4578-4601.	0.8	17
501	Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nature Genetics, 2007, 39, 733-740.	9.4	691
502	CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nature Immunology, 2007, 8, 1324-1336.	7.0	152
503	Protease Inhibitors as Immunomodulatory Drugs for HIV Infection. Clinical Pharmacology and Therapeutics, 2007, 82, 248-250.	2.3	8
504	Loss of T cell responses following long-term cryopreservation. Journal of Immunological Methods, 2007, 326, 93-115.	0.6	88

#	ARTICLE	IF	CITATIONS
505	Adherence-resistance relationships to combination HIV antiretroviral therapy. <i>Current HIV/AIDS Reports</i> , 2007, 4, 65-72.	1.1	156
506	A Randomized Study of Antiviral Medication Switch at Lower-Versus Higher-Switch Thresholds: AIDS Clinical Trials Group Study A5115. <i>Antiviral Therapy</i> , 2007, 12, 531-541.	0.6	18
507	Immune-Based Therapy for HIV Infection: Are Acute and Chronic HIV Infection Different Diseases?. <i>Journal of Infectious Diseases</i> , 2006, 194, 1632-1634.	1.9	16
508	Neutralizing Antibody Responses against Autologous and Heterologous Viruses in Acute versus Chronic Human Immunodeficiency Virus (HIV) Infection: Evidence for a Constraint on the Ability of HIV To Completely Evade Neutralizing Antibody Responses. <i>Journal of Virology</i> , 2006, 80, 6155-6164.	1.5	127
509	Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients. <i>Lancet, The</i> , 2006, 367, 711-713.	6.3	22
510	The risk of treatment versus the risk of HIV replication. <i>Lancet, The</i> , 2006, 367, 1955-1956.	6.3	6
511	The independent effect of drug resistance on T cell activation in HIV infection. <i>Aids</i> , 2006, 20, 691-699.	1.0	35
512	Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, 60-64.	0.9	108
513	Microbial translocation is a cause of systemic immune activation in chronic HIV infection. <i>Nature Medicine</i> , 2006, 12, 1365-1371.	15.2	3,107
514	CD8 T cell effector maturation in HIV-1-infected children. <i>Virology</i> , 2006, 347, 117-126.	1.1	11
515	Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. <i>Aids</i> , 2006, 20, 2275-2283.	1.0	239
516	Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. <i>Aids</i> , 2006, 20, 223-231.	1.0	277
517	Antiretroviral treatment of HIV infected adults. <i>BMJ: British Medical Journal</i> , 2006, 332, 1489.	2.4	51
518	Treatment Benefit on Cerebrospinal Fluid HIV-1 Levels in the Setting of Systemic Virological Suppression and Failure. <i>Journal of Infectious Diseases</i> , 2006, 194, 1686-1696.	1.9	83
519	Predictive Value of Plasma HIV RNA Level on Rate of CD4 T-Cell Decline in Untreated HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1498.	3.8	288
520	A Plea for Justice for Jailed Medical Workers. <i>Science</i> , 2006, 314, 924-925.	6.0	3
521	Prevalence of CXCR4 Tropism among Antiretroviral-Treated HIV-1-Infected Patients with Detectable Viremia. <i>Journal of Infectious Diseases</i> , 2006, 194, 926-930.	1.9	137
522	Rate of Viral Evolution and Risk of Losing Future Drug Options in Heavily Pretreated, HIV-Infected Patients Who Continue to Receive a Stable, Partially Suppressive Treatment Regimen. <i>Clinical Infectious Diseases</i> , 2006, 43, 1329-1336.	2.9	87

#	ARTICLE	IF	CITATIONS
523	Continued Evolution in gp41 after Interruption of Enfuvirtide in Subjects with Advanced HIV Type 1 Disease. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 1260-1266.	0.5	15
524	Performance of Human Immunodeficiency Virus Type 1 gp41 Assays for Detecting Enfuvirtide (T-20) Resistance Mutations. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3384-3387.	1.8	9
525	A Randomized Pilot Study Comparing Combination Therapy plus Enfuvirtide versus a Treatment Interruption followed by Combination Therapy plus Enfuvirtide. <i>Antiviral Therapy</i> , 2006, 11, 315-319.	0.6	9
526	Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. <i>Aids</i> , 2005, 19, 989-990.	1.0	25
527	Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. <i>Aids</i> , 2005, 19, 1575-1585.	1.0	13
528	Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment. <i>BMC Infectious Diseases</i> , 2005, 5, 98.	1.3	138
529	Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. <i>AIDS Research and Therapy</i> , 2005, 2, 6.	0.7	47
530	Phenotypic, Functional, and Kinetic Parameters Associated with Apparent T-Cell Control of Human Immunodeficiency Virus Replication in Individuals with and without Antiretroviral Treatment. <i>Journal of Virology</i> , 2005, 79, 14169-14178.	1.5	207
531	The Relationship between Nucleoside Analogue Treatment Duration, Insulin Resistance, and Fasting Arterialized Lactate Level in Patients with HIV Infection. <i>Clinical Infectious Diseases</i> , 2005, 41, 1335-1340.	2.9	41
532	Interruption of Treatment with Individual Therapeutic Drug Classes in Adults with Multidrug-Resistant HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2005, 192, 1537-1544.	1.9	146
533	Multidrug-resistant, dual-tropic HIV-1 and rapid progression. <i>Lancet, The</i> , 2005, 365, 1924-1925.	6.3	4
534	Strong Cell-Mediated Immune Responses Are Associated with the Maintenance of Low-Level Viremia in Antiretroviral-Treated Individuals with Drug-Resistant Human Immunodeficiency Virus Type 1. <i>Journal of Infectious Diseases</i> , 2004, 189, 312-321.	1.9	90
535	Progression of Atherosclerosis as Assessed by Carotid Intima-Media Thickness in Patients With HIV Infection. <i>Circulation</i> , 2004, 109, 1603-1608.	1.6	552
536	Central Memory CD4+ T Cell Responses in Chronic HIV Infection Are Not Restored by Antiretroviral Therapy. <i>Journal of Immunology</i> , 2004, 173, 2184-2189.	0.4	66
537	Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system. <i>Journal of NeuroVirology</i> , 2004, 10, 44-51.	1.0	2
538	Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system. <i>Journal of NeuroVirology</i> , 2004, 10, 44-51.	1.0	20
539	Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system. <i>Journal of NeuroVirology</i> , 2004, 10, 44-51.	1.0	27
540	Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 696-699.	1.3	226

#	ARTICLE	IF	CITATIONS
541	Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. <i>Aids</i> , 2004, 18, 981-989.	1.0	101
542	Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. <i>Aids</i> , 2004, 18, 1965-1966.	1.0	63
543	Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. <i>Blood</i> , 2004, 104, 942-947.	0.6	688
544	The immune response to AIDS virus infection: good, bad, or both?. <i>Journal of Clinical Investigation</i> , 2004, 113, 808-810.	3.9	57
545	The immune response to AIDS virus infection: good, bad, or both?. <i>Journal of Clinical Investigation</i> , 2004, 113, 808-810.	3.9	39
546	Treating the latent reservoir of HIV. <i>Aids Reader</i> , 2004, 14, 485-6.	0.3	0
547	Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. <i>Journal of Immunological Methods</i> , 2003, 283, 141-153.	0.6	200
548	Treatment of antiretroviral-drug-resistant HIV-1 infection. <i>Lancet</i> , The, 2003, 362, 2002-2011.	6.3	181
549	T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus-Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2003, 187, 1534-1543.	1.9	786
550	Assessing Resistance Costs of Antiretroviral Therapies via Measures of Future Drug Options. <i>Journal of Infectious Diseases</i> , 2003, 188, 1001-1008.	1.9	33
551	Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. <i>Aids</i> , 2003, 17, 361-370.	1.0	80
552	High levels of adherence do not prevent accumulation of HIV drug resistance mutations. <i>Aids</i> , 2003, 17, 1925-1932.	1.0	200
553	Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. <i>Aids</i> , 2003, 17, 1907-1915.	1.0	229
554	Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. <i>Aids</i> , 2003, 17, 53-63.	1.0	69
555	Dual Pressure from Antiretroviral Therapy and Cell-Mediated Immune Response on the Human Immunodeficiency Virus Type 1 Protease Gene. <i>Journal of Virology</i> , 2003, 77, 6743-6752.	1.5	46
556	Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection. <i>Annals of Internal Medicine</i> , 2003, 139, 258.	2.0	200
557	Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy. <i>Aids</i> , 2003, 17, 917-919.	1.0	26
558	Evolution of Phenotypic Drug Susceptibility and Viral Replication Capacity during Long-Term Virologic Failure of Protease Inhibitor Therapy in Human Immunodeficiency Virus-Infected Adults. <i>Journal of Virology</i> , 2002, 76, 11104-11112.	1.5	151

#	ARTICLE	IF	CITATIONS
559	Effect of Prolonged Discontinuation of Successful Antiretroviral Therapy on CD4+T Cell Decline in Human Immunodeficiency Virus-Infected Patients: Implications for Intermittent Therapeutic Strategies. <i>Journal of Infectious Diseases</i> , 2002, 186, 851-854.	1.9	50
560	A Phase II Randomized Study of HIV-Specific T-Cell Gene Therapy in Subjects with Undetectable Plasma Viremia on Combination Antiretroviral Therapy. <i>Molecular Therapy</i> , 2002, 5, 788-797.	3.7	275
561	CD4+T Cell Kinetics and Activation in Human Immunodeficiency Virus-Infected Patients Who Remain Viremic Despite Long-Term Treatment with Protease Inhibitor-Based Therapy. <i>Journal of Infectious Diseases</i> , 2002, 185, 315-323.	1.9	103
562	Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse-Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1-Infected Protease Inhibitor-Experienced Patients. <i>Journal of Infectious Diseases</i> , 2002, 185, 599-607.	1.9	171
563	Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1. <i>Aids</i> , 2002, 16, F41-F47.	1.0	85
564	Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. <i>Aids</i> , 2002, 16, 201-207.	1.0	150
565	Supervised interruptions of antiretroviral therapy. <i>Aids</i> , 2002, 16, S157-S169.	1.0	14
566	Relationship of CD8+ T cell noncytotoxic anti-HIV response to CD4+ T cell number in untreated asymptomatic HIV-infected individuals. <i>Blood</i> , 2002, 99, 4225-4227.	0.6	33
567	Is average adherence to HIV antiretroviral therapy enough?. <i>Journal of General Internal Medicine</i> , 2002, 17, 812-813.	1.3	98
568	Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable Viremia. <i>New England Journal of Medicine</i> , 2001, 344, 472-480.	13.9	672
569	Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2733-2739.	1.4	319
570	Implications of antiretroviral resistance on viral fitness. <i>Current Opinion in Infectious Diseases</i> , 2001, 14, 23-28.	1.3	147
571	Protease inhibitor-resistant HIV-1 from patients with preserved CD4 cell counts is cytopathic in activated CD4 T lymphocytes. <i>Aids</i> , 2001, 15, 179-184.	1.0	11
572	Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient. <i>Aids</i> , 2001, 15, 117-119.	1.0	18
573	Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. <i>Aids</i> , 2001, 15, 1749-1756.	1.0	215
574	Cerebrospinal fluid response to structured treatment interruption after virological failure. <i>Aids</i> , 2001, 15, 1251-1259.	1.0	59
575	Hydroxyurea Does Not Enhance the Anti-HIV Activity of Low-Dose Tenofovir Disoproxil Fumarate. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 28, 336-339.	0.9	7
576	Nonnucleoside Reverse Transcriptase Inhibitor Resistance. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 26 Suppl 1, S25-S33.	0.9	82

#	ARTICLE	IF	CITATIONS
577	Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. <i>Nature Medicine</i> , 2001, 7, 73-79.	15.2	498
578	Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. <i>Nature Medicine</i> , 2001, 7, 712-718.	15.2	141
579	Primary and Recombinant HIV Type 1 Strains Resistant to Protease Inhibitors Are Pathogenic in Mature Human Lymphoid Tissues. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 517-523.	0.5	20
580	Durable HIV Treatment Benefit Despite Low-Level Viremia. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 224.	3.8	34
581	Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. <i>Aids</i> , 2000, 14, 2877-2887.	1.0	49
582	Determinants of Virological Response to Antiretroviral Therapy: Implications for Long-Term Strategies. <i>Clinical Infectious Diseases</i> , 2000, 30, S177-S184.	2.9	106
583	Factors influencing T-cell turnover in HIV-1-seropositive patients. <i>Journal of Clinical Investigation</i> , 2000, 105, R1-R8.	3.9	207
584	HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. <i>Aids</i> , 1999, 13, F35-F43.	1.0	382
585	Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. <i>Aids</i> , 1999, 13, 1051-1061.	1.0	118
586	Antiretroviral Therapy for HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 1998, 279, 1343.	3.8	53
587	Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. <i>Aids</i> , 1998, 12, F97-F102.	1.0	90
588	Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-(<i>R</i>)-Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 Td ()-(Pho HIV-Infected Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 2380-2384.	1.4	157
589	Genotypic-resistance assays and antiretroviral therapy. <i>Lancet, The</i> , 1997, 349, 1489-1490.	6.3	22
590	Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. <i>Lancet, The</i> , 1996, 348, 1547-1551.	6.3	74
591	Maintenance of normal rat mammary epithelial cells by insulin and insulin-like growth factor 1. <i>Experimental Cell Research</i> , 1988, 174, 448-460.	1.2	59
592	LOXL-2 and TNC-C are markers of liver fibrogenesis in HCV/HIV-, HIV- and HCV-infected patients. <i>Biomarkers in Medicine</i> , 0, , .	0.6	1